Retail traders speculate that Novo Nordisk could bid up to $40 billion for Viking Therapeutics after Viking launched a Phase 1 trial of VK3019 and prepares Q3 maintenance dosing data for VK2735. CEO Mike Doustdar’s comments at the JPMorgan conference confirmed capacity for $20–$40 billion acquisitions.
Retail traders have speculated that Novo Nordisk could bid up to $40 billion for Viking Therapeutics following the launch of a Phase 1 trial for weight-loss candidate VK3019 and anticipation of Q3 maintenance dosing data for VK2735.
At the JPMorgan conference, Novo Nordisk CEO Mike Doustdar stated the company could pursue acquisitions ranging from $20 billion to $40 billion, highlighting financial firepower for peptide-based obesity assets.
Viking is advancing subcutaneous and oral formulations of VK2735 through Phase 3 studies in obesity and type 2 diabetes, offering a dual amylin-calcitonin receptor mechanism that could complement Novo Nordisk’s obesity franchise.
